HaoSi Bio Completes RMB 200 Million Series B+ Financing, Demonstrating the Vast Potential of Mass Spectrometry in Clinical Diagnostics

VCBeat has learned that Beijing Haosi Biotechnology Co., Ltd. (“Haosi Biotech”), a leading clinical mass spectrometry company in China, recently announced the completion of its RMB 200 million Series B+ financing round. The round was led by Qiming Venture Partners, with participation from YuanBio Venture Capital, Xiamen C&D Emerging Industry Equity Investment Co., Ltd., and existing investor Sino-Ocean Capital. CEC CAPITAL served as the exclusive financial advisor.

The proceeds from this round of financing will be used to advance the clinical development and regulatory filing of the company’s proprietary diagnostic products, support R&D of mass spectrometry instrument hardware, and expand clinical market promotion and outreach, thereby establishing a comprehensive integrated framework spanning R&D, product development, and commercialization.

Just five months after completing its Series B financing in December 2020, Haosi Biotechnology secured additional investment from top-tier domestic institutional investors. The rapid pace and substantial amount of this financing underscore the broad development prospects of mass spectrometry technology in the field of clinical medicine;Haosi Biotechnology has become the first company in the industry to integrate upstream and downstream sectors, establishing a virtuous closed-loop ecosystem for clinical mass spectrometry.

Beijing Haosi Biotechnology Co., Ltd. was co-founded in March 2016 by a team of PhD holders who returned to China from overseas. The company’s development goal is to target the world’s most advanced scientific research, break through key technological bottlenecks, develop a series of products and technologies with full independent intellectual property rights, and establish a disease diagnosis, treatment, and health service system with distinct Chinese characteristics.

After five years of development, Haosi Biotechnology has rapidly grown into a national high-tech enterprise integrating the R&D and manufacturing of chromatography-mass spectrometry instruments, production of automated sample pretreatment instruments, clinical chromatography-mass spectrometry diagnostic kits, third-party medical testing laboratories, and clinical proteomics and metabolomics research. Haosi Biotechnology has established two major R&D centers in Beijing and Suzhou, built a 6,800-square-meter GMP-compliant production base in Taizhou China Medical City, and set up third-party medical testing laboratories in Beijing, Sichuan, and Jiangsu, with its business coverage extending across China.

Haosi Biotechnology has upgraded and iterated its chromatography-mass spectrometry analytical instruments, previously used in food, chemical, pharmaceutical, and military industries, into specialized medical devices. By integrating automated functions such as barcode scanning, sample pretreatment, and oscillating centrifugation at the front end, the company has transformed cumbersome and complex procedures into “foolproof” one-click operations. Furthermore, with clinical testing kits built directly into the instruments, Haosi Biotechnology addresses the most significant pain point in clinical mass spectrometry.

Haosi Biotechnology has independently developed three exclusive diagnostic products that address critical clinical needs: an early diagnosis kit for Alzheimer's disease, a prostate cancer detection kit, and a cardiovascular disease detection kit.

Haosi Biotechnology has become the first company in the industry to establish a complete closed-loop and healthy ecosystem by integrating instrument hardware, automated processing, and other upstream and downstream enterprises, while incorporating its self-developed clinical testing kits to achieve automation and closed-system operation in clinical mass spectrometry.

Haosi Biotechnology has also jointly established R&D centers and research platforms with numerous renowned domestic and international universities and research institutes, promoting the standardization of China’s mass spectrometry industry and channeling the translational applications of mass spectrometry technologies to address a broader range of clinical needs.

Comprehensive collaboration with Westlake University, becoming the first IVD company held by Westlake University, established the Haosi-West Lake Precision Medicine Center, leveraging Westlake University’s strengths in basic scientific research to rapidly and effectively translate clinical chromatography-mass spectrometry research achievements into clinical testing services and diagnostic kits.

In collaboration with clinical experts from the Mayo Clinic in the United States, a joint R&D center has been established to introduce the most advanced clinical mass spectrometry detection systems from Europe and the United States into China. Working alongside domestic regulatory authorities, we have jointly formulated industry standards for clinical chromatography and mass spectrometry, launched external quality assessment programs, and promoted the healthy and orderly development of the entire industry.

Driven by Professor Gert Lubec, Co-founder of the Company and Fellow of the Austrian Academy of Sciences, we have jointly established a proteomics and metabolomics research platform with the internationally renowned mass spectrometry platform at the Fraunhofer Institute in Germany. Leveraging mass spectrometry technology to analyze and detect human blood, urine, saliva, and feces, we aim to identify novel disease biomarkers for cardiovascular, cerebrovascular, and oncological conditions.

Dr. Li Lin, Founder and CEO of Haosi Biotechnology, stated:“We extend our gratitude to both new and existing investors for their recognition of Haosi Biotechnology. Over the past five years, Haosi Biotechnology has evolved from a provider of single-disease testing services into a comprehensive solutions supplier with breakthroughs across multiple disease areas, offering an integrated portfolio that encompasses diagnostic kits, mass spectrometers, data analytics, and collaborative industry-academia-research services.”"In the future, we will continue to uphold the philosophy of 'making mass spectrometry simple' and work closely with our partners to make the greatest possible contribution to the rise of China’s in vitro diagnostics industry based on mass spectrometry testing."

Liang Yingyu, Managing Partner at Qiming Venture Partners, the lead investorstated: “Haosi Biotechnology’s three featured testing panels, closely aligned with actual clinical needs—early diagnosis of Alzheimer’s disease, prostate cancer detection, and cardiovascular disease testing—address deep-seated pain points in the current clinical diagnostics field, such as low accuracy, high costs, and inefficiency.For instance, there are over 50 million Alzheimer’s disease patients worldwide, yet there is currently no rapid, high-quality diagnostic product available in clinical practice. Haosi Biotechnology’s related research is world-leading and holds significant clinical value. We look forward to Haosi Biotechnology leading the development of the clinical mass spectrometry testing industry in China and globally, thereby benefiting more patients.”

Dr. Lin Yi, Managing Partner at YuanBio Venture Capital, stated, “The clinical mass spectrometry testing sector remains a blue ocean market with a potential size exceeding RMB 10 billion. As China is still in the early stages of development in this field, we are highly optimistic about its future prospects.”“Haosi Biotechnology holds unique advantages in China’s clinical mass spectrometry field, backed by a highly experienced R&D team and a diverse, distinctive product portfolio. As the applications of mass spectrometry detection technology continue to expand, we firmly believe that the company has tremendous growth potential in clinical diagnostics, and we look forward to seeing it achieve even greater leapfrog development following this round of financing.”

Song Huaying, Deputy Director of C&D Emerging Industry Investment, stated“Haosi Biotechnology has a clear product portfolio strategy and has obtained multiple registration certificates in the fields of routine and innovative clinical mass spectrometry testing.The Company generates revenue through kit sales.andThird-party clinical laboratory services and other business models serve hospitals at various levels, meeting the multi-tiered and evolving diagnostic needs of clinical practice.We look forward to Haosi Biotechnology driving greater development of mass spectrometry testing in China and better serving the clinical needs of the country.”

Wei Shihan, Managing Director of Oceanwide Capital, stated, “Haosi Biotechnology is a project in which we have long held a positive outlook and have continuously increased our investment. The company boasts both the breadth of coverage with dozens of routine testing products and proprietary innovations that address unmet needs in disease areas, establishing exceptionally high competitive barriers.”Meanwhile, the Company’s one-stop “hardware + reagents + services” solution has transformed the existing landscape in which hospitals collaborate separately with consumable and instrument manufacturers, pioneering a more efficient and convenient business model and driving comprehensive development in China’s clinical mass spectrometry sector. We look forward to the Company reaching new heights following this round of transaction. Ocean Capital will also maintain long-term cooperation with Haosi Biotechnology to achieve mutual success and create greater value for society.”

As the exclusive financial advisor for this transaction, Li Jin, Managing Director of CEC CAPITAL, stated: “Haosi Biotechnology is the leading enterprise in the field of clinical mass spectrometry applications in China, dedicated to simplifying and popularizing clinical mass spectrometry testing. It not only applies the translation of mass spectrometry technology to the clinical field but also introduces mature testing items from abroad to China.”Haosi Biotechnology’s multiple third-party testing centers and diverse range of specialized reagent kits ensure the company’s comprehensive capabilities in the field of clinical mass spectrometry."We are delighted to once again assist Haosi Biotechnology in closing its latest round of financing. We firmly believe that the company is poised to lead the rapid development of China’s clinical mass spectrometry industry, and we look forward to seeing it leverage emerging technologies to benefit more patients."

Qiming Venture Partners was established in 2006 and has successively set up offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston, and the San Francisco Bay Area. Currently, Qiming Venture Partners manages nine US dollar funds and six RMB funds, with total assets under management reaching $5.9 billion. Since its inception, the firm has focused on investing in outstanding early-stage and growth-stage companies in sectors such as TMT and Healthcare. To date, Qiming Venture Partners has invested in more than 380 high-growth innovative enterprises, among which over 130 have achieved exits through listings on exchanges including the New York Stock Exchange (NYSE), NASDAQ, the Hong Kong Stock Exchange (HKEX), the Taipei Exchange (TPEx), the Shanghai Stock Exchange (SSE), and the Shenzhen Stock Exchange (SZSE), as well as through mergers and acquisitions. Additionally, more than 40 of its portfolio companies have become industry-recognized unicorns and super unicorns.

YuanBio Venture Capital is an investment firm focused on the early and growth stages of the healthcare sector. Headquartered in BIOBAY, it extends its reach across China and globally. The firm currently manages RMB and USD funds with a combined total of nearly RMB 6 billion, having completed investments in over 100 high-quality projects. Its portfolio primarily covers new drug development, innovative medical devices, diagnostics and precision medicine, as well as healthcare services. YuanBio has achieved substantial investment returns and has been repeatedly recognized as one of the Top 10 Venture Capital Funds in China’s healthcare sector and one of the most active healthcare investment institutions in China. Leveraging its focused strategy and extensive industry resources, YuanBio Venture Capital is committed to becoming one of the most successful healthcare venture capital funds in China.

C&D Emerging Investment is a corporate venture capital institution backed by the Fortune Global 500 company C&D Group. Established in 2014, the company is committed to its mission of “pioneering new value and helping more high-growth new-economy enterprises achieve better development,” with a strategic focus on emerging sectors such as healthcare, advanced manufacturing, and TMT/consumer industries.

Sino-Ocean Capital was established in February 2013 as a professional institution specializing in alternative asset management. Its business scope includes real estate investment, private equity investment, structured investment, and strategic and innovative investment.

Sino-Ocean Capital consistently adheres to the alternative asset management philosophy of prudence, responsibility, collaboration, and empowerment. Leveraging its professional and distinctive investment acumen and value discovery capabilities, and through a full-cycle asset management business model encompassing “fundraising, investment, management, and exit” as well as industrial synergy, Sino-Ocean Capital helps partners enhance value, achieves effective management of entrusted funds and co-creation of shared value, and ultimately delivers returns to shareholders and society.

CEC CAPITAL is a leading investment bank for China’s new economy, focusing on the global TMT, consumer, and healthcare sectors. In addition to its investment banking services, CEC CAPITAL manages one RMB-denominated fund and one US dollar-denominated fund. The firm has offices in Beijing, Shanghai, Los Angeles, and San Francisco, and holds a license to operate in the U.S. securities market.

The healthcare and medical industry is a key focus area where CEC Capital holds significant advantages, having ranked as the new-economy investment bank with the highest number of healthcare industry transactions in China for four consecutive years. Furthermore, CEC Capital boasts the largest, most professional, and most comprehensively integrated healthcare investment banking team in China.